Alzheimer’s-related mutations may disrupt nerve connections to muscles
- Mutations linked to hereditary Alzheimer's disease disrupted the connection between motor neurons and healthy muscle cells in a laboratory model.
- The experimental system had no brain or spinal cord, suggesting that the mutations may directly affect peripheral nerves.
- The study does not establish whether changes in gait can serve as an early diagnostic sign in patients.
What the experiment with nerves and muscles showed
Alzheimer's disease is usually associated with memory loss, confusion, and cognitive decline. However, in some people, changes in balance, coordination, or gait can occur years before noticeable problems with thinking. Researchers at the University of Central Florida tested whether some of these motor impairments might arise not only from changes in the brain, but also from the direct effects of disease-linked mutations on the nerves that control muscles.
The team studied a hereditary form of Alzheimer’s disease—a rare variant that usually develops earlier than the more common form, between the ages of 40 and 65. In a laboratory system, motor neurons with mutations linked to this variant disrupted the connections through which nerve cells control muscles. This happened even though the model completely lacked a brain and spinal cord—that is, the central nervous system.
This finding changes how we frame the question of what might cause early movement problems. If the neuromuscular connection is disrupted directly by mutations, motor symptoms cannot be explained solely by damage to the brain. The study’s leaders, James Hickman and Xufan “Nadine” Guo, believe that motor problems may appear before central symptoms. But the study identified an effect in a laboratory model; it did not establish when such changes appear in people.
Why the Peripheral Nervous System Matters
Motor neurons send muscles the signals they need to contract and move. Nerves located outside the brain and spinal cord are part of the peripheral nervous system; they help relay signals between the central nervous system and the rest of the body. Researchers have shown that mutations linked to inherited Alzheimer’s disease can disrupt this signaling at the junction between a nerve cell and muscle tissue.
To test this idea, scientists created a model of the neuromuscular junction—the site where a motor neuron interacts with a muscle cell. It included healthy muscle cells and motor neurons derived from stem cells carrying mutations linked to the familial form of the disease. The researchers then assessed how effectively the altered neurons sent signals to the healthy muscle tissue. The brain and spinal cord were deliberately left out of this system.
The absence of a central nervous system made it possible to distinguish the potential direct effects of the mutations on the neuromuscular connection from the consequences of brain damage. The experiment found that the altered neurons were less able to support normal interactions with muscles. Hickman noted that this is the first demonstration that peripheral nervous system dysfunction can arise directly from such mutations. This is a finding from a laboratory model, not confirmation that all the disease’s motor symptoms have a single cause.
How the researchers built the model on a chip
The team used “human-on-a-chip” technology developed and manufactured by Hesperos, a company co-founded by Hickman. These miniature systems combine different types of human cells under controlled conditions to reproduce specific biological processes. Unlike experiments with isolated cells, they make it possible to study how tissues interact, rather than just the response of a single cell type.
Researchers used stem cells because they can develop into specialized cells, including motor neurons. Neurons with mutations were paired with healthy muscle tissue, and signal transmission was studied. Such models also offer an alternative to animal experiments: as the study source explains, animal models do not always accurately reflect how human diseases behave. However, a cell-based system is still a laboratory model, not an observation of patients.
The neuromuscular junction is essential for voluntary movement: a signal travels along a motor neuron, triggers an interaction with a muscle, and causes it to contract. This sequence is involved in walking, maintaining posture, lifting objects, and precise movements. Disrupted signal transmission could therefore potentially affect various motor functions. The study examined how the connection between nerve and muscle cells worked; it did not measure the gait or balance of people with Alzheimer’s disease.
What the results mean—and what they do not yet prove
For now, the practical significance of the finding lies primarily in opening a new direction for studying symptoms. If movement disorders can indeed arise outside the brain, approaches targeting only the central nervous system may not address problems in the peripheral nerves. Guo also pointed to the possibility of earlier intervention if changes in movement can be detected. But the study did not test a diagnostic tool or show that any particular gait feature can predict disease.
Preserving motor function may matter for more than physical health. The publication notes that regular physical activity is associated with better cognitive well-being; therefore, supporting the ability to move may also be important for brain health. This is a possible additional reason to study peripheral manifestations of the disease—not evidence that intervening in the neuromuscular connection slows or prevents cognitive decline.
The study was led by Professor James Hickman and Research Professor Xiufang “Nadine” Guo, together with scientists from Hesperos. The work was funded by the National Institute on Aging at the U.S. National Institutes of Health, and the findings were published in the Alzheimer’s Association journal Alzheimer’s & Dementia. The next question is whether the disruption observed in the cellular model will be confirmed in people and whether it will prove to be an early and reliable enough marker for clinical use.
Source: ScienceDaily
